Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Money Flow Index

Score

0.9

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 4 100.8 1.00% % 32.3% % 129.2%
SHORT 4 75.0 0.25% 0.33% 2.1% -25.6% -74.8%

Summary

Technical Analysis

Ra Pharmaceuticals Inc (RARX)


Indicator:

MONEY FLOW INDEX


Last Signal:

NEUTRAL


Trading: NO POSITION
Signal Strength: MEDIUM


Money Flow Index (MFI) is a volume-based indicator it could be used in technical analysis to measure the strength of money flow in and out of a security index and market. The principle of MFI calculation is a comparison of positive money flow to negative money flow. MFI is also known as volume-weighted RSI. MFI starts with the typical price for each period. The same as RSI the MFI scale is between 0 and 100.

Calculation: Money Flow Index (MFI):
1) Typical Price = (High + Low + Close)/3;
2) Raw Money Flow = Typical Price x Volume;
3) Money Flow Ratio = (14-period Positive Money Flow)/(14-period Negative Money Flow);
4) Money Flow Index = 100 - 100/(1 + Money Flow Ratio)


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Money Flow Index

Download
Company Close Change(%) Volume Value Signal
ARAY Accuray Incorporated 3.95 7.9 2,162,586 71.22 NEUTRAL
GBLI Global Indemnity Plc 32.56 6 9,228 67.5 NEUTRAL
TBK Triumph Bancorp 40.63 5.6 320,177 53.28 NEUTRAL
TLGT Teligent 0.42 5.5 1,235,129 54.87 NEUTRAL
ADRO Aduro Biotech 1.48 5 1,056,005 68.32 NEUTRAL
SYRS Syros Pharmaceuticals 8.2 4.9 153,243 63.19 NEUTRAL
XENT Intersect Ent 25.17 4.7 1,131,415 30.39 NEUTRAL
MGI Moneygram 2.68 4.7 2,612,033 68.09 NEUTRAL
FARM Farmer Brothers 13.38 4.4 116,584 33.14 NEUTRAL
TRUP Trupanion Inc 33.32 4.2 261,897 39.9 NEUTRAL